Variations [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2008-08-25 13:06 (6516 d 23:39 ago) – Posting: # 2246
Views: 28,351

Dear D. Labes!

OK, reading all the sections again, I would say they can be shorted into something like: 'The comparative medicinal product in any bioequivalence study (including variations to a generic product) should be the reference medicinal product authorised in the Community, on the basis of a complete dossier [...].'

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
294 visitors (0 registered, 294 guests [including 19 identified bots]).
Forum time: 12:46 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5